We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+33.27%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$22.8M
Cap. Flow
+$4.67M
Cap. Flow %
1.71%
Top 10 Hldgs %
26.58%
Holding
166
New
40
Increased
8
Reduced
21
Closed
32

Top Buys

Rank Stock Value
1
BLRX
BioLineRX
BLRX
+$5.92M
2
PLRX icon
Pliant Therapeutics
PLRX
+$4.11M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$3.89M
4
RMD icon
ResMed
RMD
+$3.87M
5
BCAB icon
BioAtla
BCAB
+$3.62M

Top Sells

Rank Stock Value
1
STAA icon
STAAR Surgical
STAA
+$5.32M
2
LNTH icon
Lantheus
LNTH
+$3.48M
3
ESPR
Esperion Therapeutics
ESPR
+$3.45M
4
DXCM icon
DexCom
DXCM
+$3.28M
5
LIVN icon
LivaNova
LIVN
+$3.12M

Sector Composition

Rank Sector Weight
1 Healthcare 79.05%
2 Financials 10.08%
3 Industrials 0.61%
4 Consumer Staples 0.24%
5 Communication Services 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLU
1
DELISTED
BELLUS Health Inc.
BLU
$12M 4.38%
1,132,000
+220,000
+24% +$2.34M
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$10.3M 3.78%
525,000
-90,000
-15% -$1.81M
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
$8.27M 3.03%
160,000
– –
PEPL
4
DELISTED
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
$7.34M 2.69%
735,000
– –
ADMA icon
5
ADMA Biologics
ADMA
$2.04B
$7.01M 2.57%
2,883,710
-1,116,290
-28% -$2.68M
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$6.13M 2.25%
1,750,000
– –
INSM icon
7
Insmed
INSM
$22.6B
$5.77M 2.12%
268,000
– –
GH icon
8
CALL
Guardant Health
GH
$19B
$5.38M 1.97%
100,000
– –
MBTC
9
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
$5.17M 1.89%
500,000
– –
GKOS icon
10
Glaukos
GKOS
$8.89B
$5.16M 1.89%
97,000
-17,000
-15% -$877K
AKRO
11
DELISTED
Akero Therapeutics
AKRO
$4.77M 1.75%
+140,000
New +$2.14M
ITCI
12
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.65M 1.71%
100,000
+25,000
+33% +$1.31M
XTNT icon
13
Xtant Medical Holdings
XTNT
$59.7M
$4.5M 1.65%
6,246,291
– –
PLRX icon
14
Pliant Therapeutics
PLRX
$66.3M
$4.49M 1.65%
+215,000
New +$4.11M
ESPR
15
DELISTED
Esperion Therapeutics
ESPR
$4.42M 1.62%
659,869
-503,000
-43% -$3.45M
BCAB icon
16
BioAtla
BCAB
$5.86M
$4.26M 1.56%
+11,060
New +$3.62M
ILMN icon
17
Illumina
ILMN
$29.2B
$4.2M 1.54%
22,616
+12,336
+120% +$2.44M
RYTM icon
18
Rhythm Pharmaceuticals
RYTM
$7.41B
$4.17M 1.53%
+170,000
New +$3.16M
VRNA
19
DELISTED
Verona Pharma
VRNA
$4.13M 1.51%
+404,000
New +$3.41M
KPTI icon
20
Karyopharm Therapeutics
KPTI
$161M
$4.09M 1.5%
50,000
+3,333
+7% +$249K
ATXS
21
DELISTED
Astria Therapeutics
ATXS
$4.02M 1.47%
+445,000
New +$2.98M
EUCR
22
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$4.01M 1.47%
400,000
– –
ANGO icon
23
AngioDynamics
ANGO
$593M
$3.99M 1.46%
195,000
+155,360
+392% +$3.41M
BLRX
24
BioLineRX
BLRX
$12.2M
$3.84M 1.41%
+103,732
New +$5.92M
KRTX
25
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.82M 1.4%
17,000
+4,000
+31% +$810K
1
2 3 4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
LSA
Liberty Street Advisors New York $41.4M AUM 34.47% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
GC
Gruss & Co West Palm Beach, Florida $42.8M AUM 49.41% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return

Altium Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Altium Capital Management held 166 positions worth $273M, up 9.1% from $250M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Altium Capital Management's Q3 2022 filing shows 40 new, 8 increased, 21 reduced and 32 closed positions. Its largest new stake was BioLineRX: 103,732 shares worth $3.84M. The largest sale was STAAR Surgical, an estimated $5.32M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 74% a quarter earlier, followed by Financials and Industrials.

  • Altium Capital Management's largest Q3 2022 buy was BioLineRX: 103,732 shares worth $3.84M.
  • Altium Capital Management added most to AngioDynamics in Q3 2022, an estimated $3.41M increase.
  • Altium Capital Management's biggest Q3 2022 reduction was Lantheus, cutting an estimated $3.48M.
  • Altium Capital Management fully exited STAAR Surgical in Q3 2022, selling an estimated $5.32M.
  • Altium Capital Management's ten largest holdings make up 27% of its $273M portfolio in Q3 2022.
  • Altium Capital Management opened 40 new positions and closed 32 in Q3 2022.
  • Altium Capital Management's portfolio value rose 9.1% quarter-over-quarter to $273M.

Based on Altium Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.